GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cybin Inc.
Shares of Cybin, a biotech company researching psychedelics for the treatment of mental disorders, are a highly speculative bet. Their price is driven not by financial performance, but by clinical trial results and changes in legislation regarding these substances.
Share prices of companies in the market segment - Pharma psycho
Cybin Inc. is a biotech company developing psychedelic-based drugs for the treatment of mental disorders such as depression and anxiety. We classify it as "Pharmaceuticals (Psychedelics)," one of the newest and most disruptive fields. The chart below shows the dynamics of this high-risk but promising sector.
Broad Market Index - GURU.Markets
Cybin is a Canadian biotech company developing psychedelic-based drugs for the treatment of mental disorders. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
CYBN - Daily change in the company's share price Cybin Inc.
Shares of Cybin, a company researching psychedelics, exhibit extreme volatility, as measured by change_co. This reflects sensitivity to clinical trial results. This metric is important for analyzing the innovative biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Cybin Inc. is a biotech company working with psychedelics. This chart highlights the sector's extreme volatility. Comparison with CYBN's performance helps assess it as a high-risk asset, dependent on clinical data and regulatory changes.
Daily change in the price of a broad market stock, index - GURU.Markets
Cybin operates in the cutting-edge and therefore volatile field of biotechnology, developing psychedelic-based drugs. News of clinical trials triggers sharp stock movements, which in turn become part of the overall "noise" and market dynamics, whose combined daily momentum is reflected in this chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cybin Inc.
Cybin Inc.'s year-over-year performance is a story about the development of a new generation of psychedelic drugs. Its 12-month market cap depends entirely on progress in clinical trials of its modified versions of psilocybin and DMT. Success could offer shorter, more effective treatments for depression and other disorders.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Cybin Inc. is a biotech company pioneering the development of psychedelic therapy for the treatment of mental disorders. Its stock price is entirely speculative and based on investor confidence in the future potential of this innovative, yet controversial, approach to medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cybin, a biotech company researching psychedelics, is one of the most speculative stories on the market. Its stock price is completely unrelated to the economy. Its price chart reflects the hopes, risks, and regulatory changes surrounding one of the most controversial areas of medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cybin Inc.
Cybin is at the forefront of psychedelic therapy development. Its pricing is based almost entirely on clinical trial expectations. Monthly fluctuations on the chart reflect progress in R&D: any positive data or steps toward regulatory approval trigger a surge in interest, while delays lead to a decline.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Cybin is a biotech company pioneering the development of psychedelic-based therapeutics for the treatment of mental disorders such as depression and anxiety. The chart below illustrates the overall dynamics of this nascent sector, reflecting the high interest and risks associated with revolutionary approaches to mental health.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of companies developing psychedelic-based therapies are among the most speculative stories on the market. The chart below shows the overall risk appetite. Is Cybin Inc. moving with extreme amplitude, reacting to the slightest changes in investor sentiment?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cybin Inc.
Shares of Cybin, a biopharmaceutical company developing psychedelic drugs for the treatment of mental disorders, reflect the promise and risks of this revolutionary field on a weekly basis. Prices react sharply to clinical trial data and regulatory changes.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Cybin develops psychedelic-based therapeutics—a niche where news about clinical trials and regulatory decisions impact everyone. The chart below is your tool for analysis: is Cybin's weekly stock performance driven by unique advances in its research or a reaction to events affecting the entire sector?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cybin is a biotech company working with psychedelics. This is a highly speculative and newsworthy space. The chart will reveal whether Cybin shares exist in a separate universe, reacting solely to news about clinical trials and regulatory matters, or whether investors' risk appetite is still tying them to the market.
Market capitalization of the company, segment and market as a whole
CYBN - Market capitalization of the company Cybin Inc.
Cybin's market capitalization tells the story of a biotech company at the forefront of the psychedelic revolution in medicine. Its volatile price chart is a barometer of sentiment in this speculative sector. Its dynamics reflect not revenue but progress in clinical trials, regulatory news, and investor confidence in the potential of psychedelics as a new class of medicine.
CYBN - Share of the company's market capitalization Cybin Inc. within the market segment - Pharma psycho
Cybin is a biotech company leading the development of psychedelic drugs for the treatment of mental disorders. Its market capitalization reflects the enormous potential, but also the high regulatory risks, of this new class of therapy. The chart below will show how much the market is betting on this medical revolution.
Market capitalization of the market segment - Pharma psycho
Cybin is a company at the forefront of psychedelic research for the treatment of mental disorders. The chart below shows the market capitalization of this nascent sector. Its extreme volatility reflects both the revolutionary potential of these substances and the enormous regulatory and clinical hurdles.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cybin is a biotech company developing psychedelic-based drugs for the treatment of mental disorders. Its market cap represents a bold bet that substances previously considered taboo will become a new class of medicine. Its volatility reflects the revolutionary yet risky changes in psychiatry.
Book value capitalization of the company, segment and market as a whole
CYBN - Book value capitalization of the company Cybin Inc.
Cybin's foundation is its capital, which is invested in clinical trials of psychedelic drugs for the treatment of mental disorders. This is a real, scientific foundation for a potentially revolutionary approach to psychiatry. How has this innovative, yet risky, asset evolved? The chart below shows the dynamics of investments in this emerging field.
CYBN - Share of the company's book capitalization Cybin Inc. within the market segment - Pharma psycho
Cybin is a biotech company developing psychedelic drugs for the treatment of mental disorders, which requires R&D labs. The chart shows the share of these science-intensive assets, reflecting the physical foundation of its innovative research.
Market segment balance sheet capitalization - Pharma psycho
Cybin develops psychedelic drugs for the treatment of mental disorders. It's a science-intensive business, where patents and research are key assets. The chart below shows how "light" the company's resources are at the forefront of neuroscience.
Book value of all companies included in the broad market index - GURU.Markets
Cybin Inc. is a pioneer in the development of psychedelic therapeutics. The company's book value is derived from its research laboratories, capital for clinical trials, and a portfolio of patents for new molecules. The chart shows the material foundation upon which innovations in the treatment of mental disorders are built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cybin Inc.
Cybin's balance sheet is capital. But the market sees it as a pioneer in psychedelic medicine. The chart shows a huge "hope factor": how many times higher investors value the potential of its drugs for treating mental disorders than all of its current assets. This is a bet on a revolution in psychiatry.
Market to book capitalization ratio in a market segment - Pharma psycho
Cybin is a biotech company at the forefront of psychedelic-based therapeutic development. Its value is almost entirely dependent on the success of clinical trials. The chart reflects the enormous investor expectations for this revolutionary field of medicine.
Market to book capitalization ratio for the market as a whole
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders such as depression and anxiety. Its assets include patents and clinical trial data. This chart shows the overall market valuation, but how do investors evaluate the potential of controversial but promising molecules in psychiatry?
Debts of the company, segment and market as a whole
CYBN - Company debts Cybin Inc.
Cybin is at the forefront of pharmaceutical development, developing psychedelic-based drugs. This is a completely new and high-risk field. This chart shows how the company is raising capital to fund clinical trials that could revolutionize the treatment of mental disorders.
Market segment debts - Pharma psycho
Cybin Inc. is at the forefront of developing psychedelic drugs to treat mental disorders such as depression. This is a revolutionary but risky field. This chart shows how the company is raising capital to conduct expensive and complex clinical trials in the new and highly regulated pharmaceutical industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cybin Inc.
Cybin develops psychedelic drugs to treat mental disorders. This chart shows how the biotech startup is using debt to fund innovative but risky clinical trials. It's a bet on future legalization and medical use, with every dollar of debt an investment in a potential revolution in psychiatry.
Market segment debt to market segment book capitalization - Pharma psycho
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. This chart shows the leverage in the cutting-edge but risky psychopharmacology sector. It helps understand how companies finance their unique clinical research and how Cybin manages capital on its path to therapy legalization.
Debt to book value of all companies in the market
Cybin Inc. is researching psychedelic drugs for the treatment of mental disorders. This is a cutting-edge but speculative field of biotechnology, financed exclusively by equity capital. A chart reflecting debt trends in the economy makes it clear that Cybin's risks lie not in the financial sphere, but in the results of its clinical trials.
P/E of the company, segment and market as a whole
P/E - Cybin Inc.
This chart for Cybin, a biopharmaceutical company developing psychedelic drugs for the treatment of mental disorders, shows the high expectations of investors. Its value reflects not current profits, but rather the belief in the revolutionary potential of this new class of drugs and the company's ability to successfully navigate clinical trials and regulatory hurdles.
P/E of the market segment - Pharma psycho
Psychedelic drug development, as Cybin does, is a new and speculative sector. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Cybin is not valued based on profits, but rather on a bet that psychedelics will be legalized and become a new class of drugs for treating mental disorders.
P/E of the market as a whole
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders such as depression and addiction. This is a new and promising, but risky, field. This chart of overall market risk appetite allows us to assess how willing investors are to invest in this revolutionary, yet unproven, therapy.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cybin Inc.
Cybin is a biotech company developing psychedelic drugs for the treatment of mental disorders. This chart reflects highly speculative expectations regarding the legalization and medical use of these substances. The trend is an estimate of the likelihood of success of its clinical programs and legislative changes.
%20P%2FE%20Cybin%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cybin-Inc.&v=1772565866709 "Chart of the company's future (projected) P/E Cybin Inc.")
Future (projected) P/E of the market segment - Pharma psycho
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. This chart shows profitability expectations for this innovative pharmaceutical. It provides insight into the market's appreciation for the potential of psychedelics to become a new class of drugs and Cybin's leadership in this field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772565866762 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders such as depression and addiction. This chart shows investors' risk appetite. For a company operating in a new and regulatoryly complex field, it reflects the market's willingness to fund breakthrough but controversial treatment approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772565866789 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cybin Inc.
Cybin Inc. is a biotech company at the forefront of developing psychedelic drugs for the treatment of mental disorders. The financial indicators presented here represent investments in clinical research. The chart illustrates the cost of the scientific journey aimed at creating a new class of mental health drugs.
Profit of companies in the market segment - Pharma psycho
Cybin is a biotech company working in the field of psychedelic medicine. It develops therapeutic drugs based on compounds such as psilocybin for the treatment of mental disorders. This chart illustrates the emerging profitability of this innovative sector, where scientific breakthroughs and regulatory changes could create an entirely new drug market.
Overall market profit
Cybin is a biotech company developing psychedelic drugs for the treatment of mental disorders. This is a cutting-edge and speculative field requiring significant investment and regulatory changes. The economic growth phase, reflected in this chart, is driving capital flows into such innovative but high-risk sectors.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cybin Inc.
Cybin is a biotech company developing psychedelic drugs for the treatment of mental disorders. The profit (or loss) forecast on this chart reflects analysts' expectations for clinical trial results and potential regulatory changes regarding such therapies. This is a long-term bet on a new paradigm in psychiatry.
%20profit%20of%20the%20company%20Cybin%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cybin-Inc.&v=1772565866923 "Graph of future (projected) profit of the company Cybin Inc.")
Future (predicted) profit of companies in the market segment - Pharma psycho
Cybin Inc. is a biotech company at the forefront of psychedelic research for the treatment of mental disorders such as depression and addiction. This chart shows the profit forecast for the psychopharmaceutical sector, providing insight into the market's perception of the commercial potential of this revolutionary, yet under-explored, field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772565867052 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Cybin is a biotech company developing psychedelic drugs for the treatment of mental disorders. This is a cutting-edge and risky field. This chart, reflecting investors' risk appetite, impacts the availability of capital for companies working at the intersection of pharmaceuticals and new treatment approaches.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772565867108 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cybin Inc.
Cybin is a biotech company at the forefront of psychedelic research for the treatment of mental disorders. This chart reflects a speculative estimate of its future potential. The revenue estimate (from research) is a bet on the legalization and medical application of these innovative therapies.
P/S market segment - Pharma psycho
Cybin Inc. is a biotech company at the forefront of psychedelic research. It is developing new psilocybin-based drugs for the treatment of mental disorders such as depression. This chart reflects investor expectations in the sector, showing how the market views the potential of this revolutionary, yet unregulated, class of drugs.
P/S of the market as a whole
Cybin is a biotech company developing next-generation psychedelic drugs for the treatment of mental disorders such as depression and anxiety. This is a cutting-edge, yet regulatoryly complex, field. This chart helps understand the market's willingness to invest in breakthrough, yet high-risk, pharmaceutical trends.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cybin Inc.
Cybin is a biotech company developing psychedelic drugs for the treatment of mental disorders. This chart shows its valuation relative to future, currently hypothetical, sales. It is a measure of investor confidence in the therapeutic potential of psychedelics and Cybin's ability to successfully complete clinical trials.
%20P%2FS%20Cybin%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cybin-Inc.&v=1772565867299 "The graph of the company's future (projected) P/S Cybin Inc.")
Future (projected) P/S of the market segment - Pharma psycho
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders such as depression and anxiety. This is a cutting-edge and regulatoryly complex field. This chart reflects the high investor expectations for the company's potential breakthrough in this new field of medicine.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772565867314 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Cybin is a biotech company developing psychedelic drugs for the treatment of mental disorders. Its future depends on the success of clinical trials and regulatory changes. This general expectations chart for CYBN is not a direct driver. The company's value is determined by scientific potential and regulatory progress in this emerging field of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772565867318 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cybin Inc.
This chart illustrates the financial trajectory of an early-stage biotech company. For Cybin, which develops psychedelic drugs for the treatment of mental disorders, it reflects funding from investors to finance clinical trials, not commercial revenue.
Sales of companies in the market segment - Pharma psycho
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. It is at the forefront of a resurgence of interest in this class of therapy. This chart reflects pharmaceutical sector revenues, and Cybin's potential breakthrough could open up an entirely new multibillion-dollar market and radically change it.
Overall market sales
Cybin is a biotech company developing psychedelic-based therapeutics for the treatment of mental disorders. The company is at the forefront of innovation in psychiatry. Its research could lead to the creation of an entirely new class of drugs, reflecting how scientific breakthroughs are shaping future healthcare markets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cybin Inc.
Cybin is a biotech company at the forefront of developing psychedelic drugs for the treatment of mental disorders such as depression and addiction. Future sales projections depend on the legalization and success of clinical trials of these innovative therapies.
%20sales%20of%20the%20company%20Cybin%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cybin-Inc.&v=1772565867440 "Schedule of future (projected) sales of the company Cybin Inc.")
Future (projected) sales of companies in the market segment - Pharma psycho
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. The outlook for the psychopharmaceutical sector reflects a shift in treatment approaches. The graph shows how open the scientific community and regulators are to adopting new therapies to address complex mental health issues.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772565867511 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Cybin is a biotech company developing psychedelic drugs for the treatment of mental disorders. Its success depends on the results of clinical trials and regulatory changes. This overall economic activity curve doesn't directly affect demand, but it may impact the availability of venture capital for research in this innovative field.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772565867560 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cybin Inc.
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. While in clinical trials, it incurs significant R&D expenditures. This chart illustrates the "cost of innovation"—the investment required to bring an entirely new class of drugs to market.
Market segment marginality - Pharma psycho
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. While in clinical trials, profitability is a future goal. This metric reflects the structure of its research investments and operating model compared to other companies in the advanced field of psychopharmacology.
Market marginality as a whole
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. This chart shows overall profitability. Compared to this, Cybin is a high-risk bet on the legalization and medical use of a new class of substances. The company is in the research phase and is not profitable.
Employees in the company, segment and market as a whole
Number of employees in the company Cybin Inc.
Cybin is a biotech company at the forefront of psychedelic research for the treatment of mental disorders. Its small team consists of scientists and drug development experts. The growth this graph could show would be a direct indicator of progress in its clinical programs and its approach to potential therapy approval.
Share of the company's employees Cybin Inc. within the market segment - Pharma psycho
Cybin Inc. is a biotech company at the forefront of psychedelic drug research for the treatment of mental disorders such as depression. This chart highlights its scientific vanguard. It reflects the percentage of neuroscientists, chemists, and psychopharmacologists working in this revolutionary and emerging field of medicine that Cybin attracts.
Number of employees in the market segment - Pharma psycho
Cybin Inc. researches and develops psychedelic drugs for the treatment of mental disorders. This graph illustrates the emergence of a new, revolutionary field in pharmaceuticals. The growing number of scientists and clinicians here demonstrates the growing interest and investment in exploring the therapeutic potential of long-prohibited substances.
Number of employees in the market as a whole
Cybin Inc. is researching psychedelic drugs for the treatment of mental disorders. This industry is in its earliest stages of development and is funded by venture capital. The overall employment trends shown in the graph do not affect Cybin. Their growth depends solely on clinical trial results and regulatory changes.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cybin Inc. (CYBN)
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. It's at the cutting edge and riskiest point in pharmaceuticals. This chart shows how the market is pricing this potential breakthrough. The astronomical market capitalization per employee reflects not current revenue, but the enormous expectations for a potential revolution in psychiatry.
%20of%20the%20company%20Cybin%20Inc.%20(CYBN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cybin-Inc.-CYBN&v=1772565868070 "Chart of market capitalization per employee (in thousands of dollars) of the company Cybin Inc. (CYBN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Cybin works in the field of psychedelic medicine, a cutting-edge field of biotechnology where the company's entire value is concentrated in intellectual property and clinical trials. This chart shows the enormous market valuation that investors assign to each scientist on the team, betting on a future breakthrough in the treatment of mental disorders.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772565868074 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Cybin is a company developing psychedelic therapies for the treatment of mental disorders. This is a cutting-edge and risky area of biotechnology. This chart reflects the employee's high valuation, as a potential breakthrough in this field could create an entirely new market and generate enormous revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772565868141 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cybin Inc. (CYBN)
Cybin is a biotech company working at the forefront of research into psychedelics (such as psilocybin) for the treatment of mental disorders such as depression. This is pure R&D. This metric is negative. It reflects how much the company invests in each scientist and physician to conduct clinical trials and navigate the complex regulatory environment for these new drugs.
%20Chart%20Cybin%20Inc.%20(CYBN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cybin-Inc.-CYBN&v=1772565868165 "Company Profit Per Employee (in thousands of dollars) Chart Cybin Inc. (CYBN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Cybin develops psychedelic drugs for the treatment of mental disorders. This is at the forefront of biotechnology. The graph represents the industry standard, but for an R&D company like CYBN, it is currently irrelevant due to the lack of revenue. All the value is generated by a small scientific team. If successful, their intellectual property could generate colossal profits per employee.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772565868183 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Cybin is a biotech company working on psychedelics for the treatment of mental disorders. This is one of the most speculative and early-stage biotech companies. Its entire staff consists of scientists and doctors conducting clinical trials. The company's profit per employee is deeply negative, reflecting solely the rate at which capital is burned through R&D in the hopes of future legalization and approval of these drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772565868216 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cybin Inc. (CYBN)
Cybin is a biotech company developing psychedelic drugs for the treatment of mental disorders. This chart reflects its status as an R&D company. Lack of revenue is normal for the clinical stage. In the future, this metric will become a measure of the commercial success of its innovative therapeutic approaches.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cybin-Inc.-CYBN&v=1772565868305 "Sales chart per company employee Cybin Inc. (CYBN)")
Sales per employee in the market segment - Pharma psycho
Cybin is a biotech company operating in the psychedelics sector. They are developing new treatments for mental disorders based on psilocybin derivatives. During the R&D phase, this metric reflects how effectively their scientific team attracts capital and generates revenue (through partnerships) in this nascent industry.
Sales per employee for the market as a whole
Cybin is a biotech company at the forefront of psychedelic research for the treatment of mental disorders. It is a 100% R&D company. This chart shows revenue per employee. Predictably, it is zero. It emphasizes that the company doesn't sell products, but rather invests in lengthy and expensive clinical trials, where its scientific staff creates future value.
Short shares by company, segment and market as a whole
Shares shorted by company Cybin Inc. (CYBN)
Cybin is a biotech company developing psychedelic drugs (based on psilocybin and DMT) for the treatment of mental disorders such as depression. This chart shows bearish bets. Bears may doubt the commercial potential of these treatments, expect strict regulatory oversight, or believe that clinical trials will not prove their effectiveness.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cybin-Inc.-CYBN&v=1772565868437 "Short Shares Chart for the Company Cybin Inc. (CYBN)")
Shares shorted by market segment - Pharma psycho
Cybin Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. This is a sector with high regulatory risk. This chart shows the overall short positions in the psychedelic medicine sector. The high short position here reflects deep investor skepticism regarding the timing of the legalization and commercialization of these methods.
Shares shorted by the overall market
Cybin is a leader in speculative psychedelic development. It's a business built on future expectations. When this market fear indicator rises, a "venture winter" freezes the sector. Investors panic and flee unprofitable biotechs, and "dream" stocks like CYBN are the first to sell off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cybin Inc. (CYBN)
Cybin develops psychedelics for the treatment of mental disorders. The stock is highly speculative. This chart can soar above 70 on positive R&D news or sector hype. Oversold levels (<30) often reflect setbacks, regulatory barriers, or risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cybin-Inc.-CYBN&v=1772565868595 "RSI 14 indicator chart for the company's stock Cybin Inc. (CYBN)")
RSI 14 Market Segment - Pharma psycho
Cybin (CYBN) is a pioneer in psychedelics. They're developing a *new generation* of (non-hallucinogenic?) *psilocybin* (from mushrooms) to treat depression. The RSI_14_Seg for "Pharma psycho" (biotech) shows the overall sentiment. The chart helps us understand: is CYBN's volatility just hype or is the *entire* sector overheated?
RSI 14 for the overall market
Cybin (CYBN), a "psychedelic" biotech. This chart is an indicator of hype and risk appetite. In times of euphoria, investors are ready to "buy the dream" of legalization. In moments of panic, investors flee unprofitable, speculative industries, and the cash spigot for companies burning billions is shut off.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CYBN (Cybin Inc.)
Cybin is a biotech company at the forefront of psychedelic research. They are developing psilocybin- and DMT-based drugs for the treatment of mental disorders. This chart shows the analysts' average 12-month price forecast. Their target price is a highly speculative bet on clinical trial success.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CYBN-Cybin-Inc.&v=1772565868658 "A chart showing analyst consensus forecasts for the expected stock price. CYBN (Cybin Inc.)")
The difference between the consensus estimate and the actual stock price CYBN (Cybin Inc.)
Cybin (CYBN) is a biotech company developing a new generation of psychedelics (psilocybin) for the treatment of mental disorders. This chart is a barometer of R&D hopes. It measures the vast gap between the speculative price and the consensus target, reflecting the enormous potential analysts see if their therapy is approved.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CYBN-Cybin-Inc.&v=1772565868664 "A chart showing the difference between the consensus forecast and the actual stock price. CYBN (Cybin Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Cybin is a leading company in the psychedelic medicine sector. It develops psilocybin (mushroom)-based medications for the treatment of depression. This chart shows analysts' overall expectations for the entire pharmaceutical (psychology) sector. It reflects whether experts believe in the legalization and commercial success of psychedelics.
Analysts' consensus forecast for the overall market share price
Cybin Inc. is a Canadian biotech company operating in the psychedelic medicine sector. They are developing psilocybin-based drugs (mushrooms) for the treatment of depression. This chart shows the overall risk appetite. For Cybin, operating in a speculative and not yet fully legalized sector, overall market optimism (risk appetite) is critical for funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cybin Inc.
Cybin is a pioneer in psychedelic biotechnology. They don't sell mushrooms, but rather develop patented, improved molecules (based on psilocybin) for the treatment of severe depression and addiction. This chart is a barometer of the psychedelic renaissance. It reflects their progress in clinical research (R&D), their patent portfolio, and the market's confidence in the FDA's approval of these drugs.
AKIMA Market Segment Index - Pharma psycho
Cybin is a Canadian biotech company at the forefront of research into psychedelics (such as psilocybin) for the treatment of mental disorders. This chart shows the average pharma sector index. It provides investors with a benchmark for how Cybin, operating in this innovative but risky niche, compares to the sector average.
The AKIM Index for the overall market
Cybin is a biotech company developing next-generation psychedelic drugs for the treatment of mental disorders. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding this speculative field of medicine.
